Chesapeake Energy Corp. is an independent oil and gas company engaged in the development, exploration, acquisition and production of onshore natural gas and oil reserves. Chesapeake owns interests in producing oil and gas wells concentrated in three primary operating areas: the Mid-Continent region of Oklahoma, western Arkansas, southwestern Kansas and the Texas Panhandle; the Gulf Coast region consisting primarily of the Austin Chalk Trend in Texas and Louisiana and the Tuscaloosa Trend in Louisiana; and the Helmet area of northeastern British Columbia.

Chesapeake Energy Corporation (NYSE:CHK)’s Financial Overview

Chesapeake Energy Corporation (NYSE:CHK) surged 9.89% yesterday to close its trading session at $7. The company has 1 year Price Target of $7.46. The stock traded with the volume of 121.99 Million shares yesterday. The firm shows the market capitalization of $6.21 Billion.

Chesapeake Energy Corporation (NYSE:CHK) reported its last quarterly earnings on Sep 16 where the firm reported its Actual EPS of $0.09/share against the analyst consensus estimate of $-0.03/share. The difference between the actual and expected EPS is $0.12 a share with a surprise factor of 400%.

The firm is trading with SMA20 of 19.64 Percent, SMA50 of 13.12 Percent and SMA200 of 34.12 percent. Chesapeake Energy Corporation has P/S value of 0.63 while its P/B value stands at 0. Similarly, the company has Return on Assets of -42.1 percent, Return on Equity of 248.6 percent and Return on Investment of -145.7 Percent. The company shows Gross Margin and Operating Margin of 55.7 percent and -63.7 percent respectively.

Many brokerage firms are involved in issuing their ratings on Chesapeake Energy Corporation (NYSE:CHK). On 10-Nov-16 Jefferies Upgrade Chesapeake Energy Corporation Stock  to Hold. Another firm also rated the stock on 25-Oct-16 where RBC Capital Mkts Upgrade the stock to Sector Perform.

The Stock currently has Analyst’ mean Recommendation of 3 where the scale is from 1 to 5, 1 means Strong Buy and 5 means Sell.

The 29 analysts offering 12-month price forecasts for Chesapeake Energy have a median target of 7.25, with a high estimate of 11.00 and a low estimate of 2.00. The median estimate represents a +3.57% increase from the last price of 7.00.

Our vendor, Zacks Investment Research, hasn’t provided us with the upcoming earnings report date.

Valeant Pharmaceuticals International, Inc. (NYSE:VRX)

Valeant Pharmaceuticals International, Inc. is a pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics. The Company produces medicines that meet the special health problems of patients. Valeant’s development pipeline strategy comprises both new compounds as well as product life cycle management. Its early and late-stage drug candidates have unique formulations and mechanisms of action including retigabine for the treatment of epilepsy and pain, taribavirin of the treatment of chronic hepatitis C, and several dermatology candidates for the treatment of rosacea, acne, and dermatological fungus. Valeant Pharmaceuticals International, Inc. is headquartered in Mississauga, Canada.

Valeant Pharmaceuticals International, Inc. (NYSE:VRX)’s Financial Outlook

The 19 analysts offering 12-month price forecasts for Valeant Pharmaceuticals have a median target of 23.00, with a high estimate of 55.00 and a low estimate of 9.00. The median estimate represents a +45.66% increase from the last price of 15.79.

Our vendor, Zacks Investment Research, hasn’t provided us with the upcoming earnings report date.

According to Zacks Investment Research, Valeant Pharmaceuticals International, Inc. has a Consensus Recommendation of 3.04. (The Scale is from 1-5 where 1 means Strong Buy and 5 means Strong Sell).

The Stock fell -7.98% and closed its last trading session at $15.79. The company has the market capitalization of $5.39 Billion. The stock has 52-week high of $119.87 and 52-Week low of $13.77. The firm touched its 52-Week high on Dec 16, 2015 and 52-Week low on Nov 8, 2016. The company has volume of 34.67 Million shares. The company has a total of 341.26 Million shares outstanding.

Valeant Pharmaceuticals International, Inc. (NYSE:VRX) in the last quarter reported its actual EPS of $1.55/share where the analyst estimated EPS was $1.75/share. The difference between the actual and Estimated EPS is $-0.2. This shows a surprise factor of -11.4 percent.

The company has YTD performance of -84.47 percent. Beta for Valeant Pharmaceuticals International, Inc. stands at -0.1 while its ATR (average true range) is 1.43. The company has Weekly Volatility of 5.72%% and Monthly Volatility of 9.88%%.

Valeant Pharmaceuticals International, Inc. has distance from 20-day Simple Moving Average (SMA20) of -12.95%, Distance from 50-Day Simple Moving Average of -26.07 percent and Distance from 200-Day Simple Moving Average of -47.92%.

The Company currently has ROA (Return on Assets) of -4.7 percent, Return on Equity (ROE) of -42.9 Percent and Return on Investment (ROI) of 3.7% with Gross margin of 73.8 percent and Operating & Profit margin of -5.2% and -22.5% respectively.